Digital Cognition Study During Long-COVID
Exploring Long-COVID Impact on Cognition Through Digital Neuropsychological Assessment
Luxembourg Institute of Health
300 participants
Apr 15, 2023
INTERVENTIONAL
Conditions
Summary
The persistence of the COVID-19 disease symptoms, such as extreme fatigue, shortness of breath, cardiovascular complications, depression and anxiety, pain, brain fog, loss of taste/smell, headaches as well as loss of memory has been evoked in many studies. This project aims at approaching the persistent symptomatology on cognition, more than 1 year after the infection. When we refer to cognition, we refer to everything associated with knowledge, that is, the accumulation of information we have acquired through learning or from our experience. We can define cognitive processes as the processes we use to incorporate new knowledge and make decisions based on it. Through these processes several cognitive functions intervene: perception, attention, memory, reasoning, language, learning, decision-making. All of these cognitive functions work together to integrate knowledge as a whole and create an interpretation of the world around us. Usually neuropsychological tests are used to evaluate cognitive problems, they consist in different exercises sometimes with words, figures to draw, images to remember, movement to repeat, numbers to link together etc. The DigiCog project here propose 1. to test and validate a very novel device, which uses the eyes movement during tasks to evaluate very quickly the cognitive functioning; 2. to study potential cognitive problems long-term after COVID-19; and 3. to explore how cognition could be preserved. Finally, this project will also help to bring the innovative device tested to the market, for accurately monitoring people with long COVID.
Eligibility
Inclusion Criteria3
- Participants who have previously participated in the Predi-COVID study (Registration number NCT04380987), or who have experienced COVID-19 at least once before 2022.
- Participants who have signed the informed consent form
- Participants aged between 25 and 65 years old
Exclusion Criteria3
- Psychological or neurological disorders history especially those detected before the COVID-19 disease (e.g. epilepsy, stroke, chronic fatigue) as well as treatment that could interfere with the assessment (e.g., antipsychotics, antidepressants, mood stabilizers, antiepileptics, benzodiazepines)
- Poor eyesight, rendering the use of the digital device impossible
- Inability to speak the proposed languages
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06391970